# Addiction Medicine Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Billie Holiday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML010-SYN-TD
- Date: 1948-04-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Constance Mayfield, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- To: Julian Ortiz, MD, Addiction Medicine
- Urgency: Within one week, on the same day as her one-week primary care visit

## Referral question

Severe opioid use disorder and moderate alcohol use disorder in a 33-year-old singer, five weeks after release from about ten months in custody, when her tolerance is low and her overdose risk high. Buprenorphine with naloxone was started today. Please confirm the medication plan and dose, advise on a medicine for her drinking that is safe with buprenorphine, and help set the monitoring and recovery plan. **S**

## Questions for the consultant

1. Is buprenorphine the right medication for her, and what dose should we aim for?
2. Which medicine for alcohol use disorder can she take with buprenorphine?
3. How should we read her liver tests, and does she need more than FIB-4 to stage fibrosis?
4. What monitoring do you advise, including urine drug testing and visit frequency?
5. How should we respond if she returns to opioid use?

## Pertinent history

Heroin use since her twenties, becoming severe in the last few years; she has sought treatment before. No opioid use since release and no withdrawal today; no medication for opioid use disorder was offered in custody. Drinking four or five drinks on most performance nights since release (AUDIT-C 8; PEth 312 ng/mL); no history of withdrawal seizures or delirium. DAST-10 7. PHQ-9 9, item 9 scored 0; structured safety assessment shows no suicidal thoughts. Urine pregnancy test negative. Today: buprenorphine with naloxone, 4 mg today and then 8 mg daily; naloxone nasal spray; thiamine; Tdap, PCV20, and first doses of hepatitis A and B vaccines. Blood tests drawn today: AST 52, ALT 38, GGT 84 U/L, albumin 4.0 g/dL, bilirubin 0.7 mg/dL, MCV 101 fL, platelets 236, creatinine 0.72 mg/dL; hepatitis C antibody, hepatitis B triple panel, and HIV test sent. She has been singled out by law enforcement many times and is wary of clinics; she asks that she decide what is shared and with whom. **S**

- Billie Holiday was born Eleanora Fagan in Philadelphia on April 7, 1915, and was raised in Baltimore by her mother, Sarah Julia "Sadie" Fagan. **D**
- Her mother died in October 1945; afterwards Holiday drank more heavily and her drug use increased as she grieved. **D**
- Holiday began using heroin in the early 1940s, and her addiction became severe in the late 1940s; she was arrested repeatedly over her heroin use in that period. **D**
- In May 1947 Holiday was arrested for narcotics possession; she pleaded guilty, was sentenced to a year and a day, and was held at the federal facility for women at Alderson, West Virginia, until her early release on March 16, 1948. **D**
- Holiday sought treatment for her addiction, at one point checking herself into an institution in the hope of breaking her habit. **D**
- Her conviction cost her the New York City cabaret card she needed to perform in clubs that served alcohol. **D**
- The Federal Bureau of Narcotics pursued Holiday for years, and later writers have described that pursuit as driven by racism and linked it to her performance of "Strange Fruit," a song against lynching. **R**

3 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: Hemoglobin: 12.4 g/dL; MCV: 101 fL (high); Platelets: 236 10*3/uL; Sodium: 138 mmol/L; Potassium: 4 mmol/L; Creatinine: 0.72 mg/dL; eGFR: 113 mL/min/1.73 m²; Glucose: 88 mg/dL; AST: 52 U/L (high); ALT: 38 U/L; GGT: 84 U/L (high); Albumin: 4 g/dL; Total bilirubin: 0.7 mg/dL; Hepatitis C antibody (signal-to-cutoff): 0.09; Hepatitis B surface antibody: 3 m[IU]/mL (low); Phosphatidylethanol (PEth): 312 ng/mL (high); PHQ-9: 9; AUDIT-C: 8; DAST-10: 7. All results are synthetic.

BP 126/80 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 68 kg; BMI 25 kg/m². All vital signs are synthetic.

## Current medications

- Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue daily **S**
- Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911 **S**
- Thiamine 100 mg oral tablet, one tablet by mouth daily **S**

## Plan so far

- Buprenorphine with naloxone started in primary care at a low first dose, then 16 mg daily, continued through any return to use; naloxone, overdose education, never using alone, and fentanyl test strips. Guideline: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021) **S**
- Liver and infection screening: liver tests and FIB-4 at intake and six months, hepatitis C antibody, hepatitis B triple panel, and HIV test, with hepatitis A and B vaccines for a person who is not immune. Guideline: Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025); Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023 (2023); Hepatitis C Virus Infection in Adolescents and Adults: Screening (2020); Human Immunodeficiency Virus (HIV) Infection: Screening (2019) **S**
- Depression screening with the PHQ-9 at each recovery visit, a structured safety assessment with a written safety plan and the 988 Suicide & Crisis Lifeline, and safety review at every visit. Guideline: Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
